title: Radiotherapy with fraction size of 2.25 Gy in T1-2 laryngeal and hypopharyngeal cancer.
abstract: This study was carried out to evaluate the influence of fraction size 2.25 Gy on local control of T1 and T2 laryngeal and hypopharyngeal cancers. Between August 2002 and December 2010, 80 patients with T1 and T2 laryngeal or hypopharyngeal cancers were treated with definitive radiotherapy with a fraction size of 2.25 Gy. Primary sites were the larynx in 69 and the hypopharynx in 11. Fifty-three patients were T1 and 27 were T2. All patients' pathology was squamous cell carcinoma except one carcinosarcoma. Radiotherapy was delivered 5 days/week with a 4-MV photon beam up to a total dose of 63.0 Gy. Median treatment time was 41 days. Statistical analysis of survival was calculated using the Kaplan-Meier method. No acute toxicity greater than grade 2 (CTCAE ver. 3.0.) including mucositis and dermatitis was observed. All but one patient had a complete response. The partial response patient received salvage surgery. The median follow-up period was 47 months (ranging from 4 to 108 months). No late toxicity greater than 1 was observed. Nine patients developed recurrence, seven local and two neck lymph nodes. Three patients died, one from laryngeal cancer and two from intercurrent diseases. The 5-year local control rates (LCRs) in the entire group, larynx T1, larynx T2 and hypopharynx T1 were 85.8%, 97.6%, 70.1% and 85.7%, respectively. The LCRs of T1 improved compared with our historical control, but not those of T2. The 2.25-Gy fraction size is safe and may have the potential to achieve good LCR in T1 lesions.
authors.affiliation: Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-ku, Chiba-city, Chiba 263-8555, Japan. kkarasaw@nirs.go.jp
authors.forename: Kumiko
authors.initials: K
authors.lastname: Karasawa
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Kunogi
authors.forename: Takahisa
authors.initials: T
authors.lastname: Hirai
authors.forename: Hidehiro
authors.initials: H
authors.lastname: Hoji
authors.forename: Hisako
authors.initials: H
authors.lastname: Hirowatari
authors.forename: Hiromi
authors.initials: H
authors.lastname: Izawa
authors.forename: Kana
authors.initials: K
authors.lastname: Ito
authors.forename: Keisuke
authors.initials: K
authors.lastname: Sasai
authors.forename: Tomohisa
authors.initials: T
authors.lastname: Furuya
authors.forename: Shuichi
authors.initials: S
authors.lastname: Ozawa
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Matsumoto
authors.forename: Shin
authors.initials: S
authors.lastname: Ito
authors.forename: Shinichi
authors.initials: S
authors.lastname: Oba
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy*; D002296:Carcinosarcoma / Q000532:radiotherapy*; D019583:Dose Fractionation, Radiation; D005260:Female; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000532:radiotherapy*; D007822:Laryngeal Neoplasms / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D011878:Radiotherapy / Q000379:methods*; D011879:Radiotherapy Dosage; D013997:Time Factors; D016896:Treatment Outcome
keywords: hypofractionated radiotherapy; hypopharyngeal cancer; laryngeal cancer